About: Inflammation inhibitors were remarkably up‐regulated in plasma of severe acute respiratory syndrome patients at progressive phase

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inflammation inhibitors were remarkably up‐regulated in plasma of severe acute respiratory syndrome patients at progressive phase Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Inflammation inhibitors were remarkably up‐regulated in plasma of severe acute respiratory syndrome patients at progressive phase
Creator	Sun, Wei Gao, Xue Jiang, Ying He, Fuchu Kuai, Xuezhang Dai, Jingquan Li, Xiaohai Qian, Xiaohong Wan, Jia Wei, Handong Ying, Wantao Zhu, Yunping
source	Medline; PMC
abstract	Severe acute respiratory syndrome (SARS) is a severe infectious disease that has affected many countries and regions since 2002. A novel member of the coronavirus, SARS‐CoV, has been identified as the causative agent. However, the pathogenesis of SARS is still elusive. In this study, we used 2‐D DIGE and MS to analyze the protein profiles of plasma from SARS patients, in the search for proteomic alterations associated with the disease progression, which could provide some clues to the pathogenesis. To enrich the low‐abundance proteins in human plasma, two highly abundant proteins, albumin and IgG, were first removed. By comparing the plasma proteins of SARS patients with those of a normal control group, several proteins with a significant alteration were found. The up‐regulated proteins were identified as alpha‐1 acid glycoprotein, haptoglobin, alpha‐1 anti‐chymotrypsin and fetuin. The down‐regulated proteins were apolipoprotein A‐I, transferrin and transthyretin. Most of the proteins showed significant changes (up‐ or down‐regulated) in the progressive phase of disease, and there was a trend back to normal level during the convalescent phase. Among these proteins, the alterations of fetuin and anti‐chymotrypsin were further confirmed by Western blotting. Since all the up‐regulated proteins identified above are well‐known inflammation inhibitors, these results strongly suggest that the body starts inflammation inhibition to sustain the inflammatory response balance in the progression of SARS.
has issue date	2006-04-28(xsd:dateTime)
bibo:doi	10.1002/pmic.200500638
bibo:pmid	16649161
has license	no-cc
sha1sum (hex)	e0a04b0898e8d86bbe07b4510618ba5f04b74815
schema:url	https://doi.org/10.1002/pmic.200500638
resource representing a document's title	Inflammation inhibitors were remarkably up‐regulated in plasma of severe acute respiratory syndrome patients at progressive phase
has PubMed Central identifier	PMC7168070
has PubMed identifier	16649161
schema:publication	Proteomics
resource representing a document's body	covid:e0a04b0898e8d86bbe07b4510618ba5f04b74815#body_text
is schema:about of	named entity 'plasma' named entity 'inflammation' named entity 'coronavirus' named entity 'protein' named entity 'haptoglobin' named entity 'pathogenesis' named entity 'plasma' named entity 'up-regulated' named entity 'WAS A' named entity 'PROTEOMIC' named entity 'DISEASE PROGRESSION' named entity 'SIGNIFICANT' named entity 'INFECTIOUS DISEASE' named entity 'ABUNDANCE' named entity 'ENRICH' named entity 'INFLAMMATORY RESPONSE' named entity 'MOST OF' named entity 'CONVALESCENT PHASE' named entity 'REMOVED' named entity 'FOUND' named entity 'PLASMA' named entity 'up-regulated' named entity 'glycoprotein' named entity 'abundant' named entity 'proteins' named entity 'proteins' named entity 'up-regulated' named entity 'provide' named entity 'phase' named entity 'down-regulated' named entity 'proteins' named entity 'However' named entity 'phase' named entity 'sustain' named entity 'comparing' named entity 'patients' named entity 'inhibitors' named entity 'transthyretin' named entity 'proteomic' named entity 'infectious disease' named entity 'SARS' named entity 'apolipoprotein A-I' named entity 'pathogenesis' named entity 'alpha-1 acid glycoprotein' named entity 'IgG' named entity 'control group' named entity 'plasma' named entity 'plasma' named entity 'up-regulated' named entity 'Severe acute respiratory syndrome (SARS)' named entity 'transthyretin' named entity 'endothelial cell' named entity 'acute inflammation' named entity 'fluorescence' named entity 'SARS' named entity 'chymotrypsin' named entity 'chymotrypsin' named entity 'lungs' named entity 'immunomodulator' named entity 'cell killing' named entity 'antioxidant' named entity 'alleles' named entity 'primary antibodies' named entity 'proteomics' named entity 'protease inhibitors' named entity 'immunomodulation' named entity 'digestion' named entity 'positive feedback' named entity 'anti-inflammatory agent' named entity 'transferrin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software